68-5

76/120

526An asterisk (＊) denotes doctoral works by Japanese students.A dagger (†) denotes doctoral works by non-Japanese students.Juntendo Medical Journal2022. 68(5), 526-549Publication ListPublications from Juntendo University Graduate School of Medicine, 2020 [3/6]Respiratory Medicine〈Original Articles〉＊ 1) Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K: Activation of insulin- like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer, 2020; 11: 140-149.) Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagi‑wara K, Kobayashi K, Nukiwa T, Inoue A: North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol, 2020; 38: 115-123.) Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim Y.K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T: Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020; 139: 195-199. 2 3＊ 4) Ko Y, Asakawa K, Tobino K, Oguma T, Hirai T, Takada T, Takahashi K, Seyama K: Multi‑center Lymphangioleiomyomatosis Sirolimus Trial for Safety Study Group. Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus. Heliyon, 2020; 6: e03345. This is a reprint of content originally published in Juntendo University HP.doi: 10.1016/j.heliyon.) Mikawa R, Sato T, Suzuki Y, Baskoro H, Kawaguchi K, Sugimoto M: p19Arf exacer‑bates cigarette smoke-induced pulmonary dysfunction. Biomolecules, 2020; 10: 462.) Shukuya T, Oyanagi J, Serizawa M, Watanabe M, Yamamoto N, Koh Y: Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau- mutant Malignant Pleural Mesothelioma Cells. Anticancer Res, 2020; 40: 1867-1874.) Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyaba‑yashi T, Sakashita H, Matsumoto Y, Tani‑gawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K: North East Japan Study Group. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previ‑ously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. Oncologist, 2020; 25: e668-e674.) Llabata P, Mitsuishi Y, Choi PS, Cai D, Francis JM, Torres-Diz M, Udeshi ND, Golomb L, Wu Z, Zhou J, Svinkina T, Aguilera-Jimenez E, Liu Y, Carr SA, Sanchez- Cespedes M, Meyerson M, Zhang X: Multi-Omics Anal‑ysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarci‑noma. Mol Cancer Res, 2020; 18: 574-584.) Suzuki K, Seyama K, Ebana H, Kumasaka T, Kuwatsuru R: Quantitative Analysis of Cystic Lung Diseases by Use of Paired Inspiratory and Expiratory CT: Estimation of the Extent of Cyst-Airway Communication and Evalua‑tion of Diagnostic Utility. Radiology: Cardio‑thoracic Imaging, 2020; 2: https://doi.org/10. 1148/ryct.2020190097 5 6 7 8 9